Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome

A report from the Children's Oncology Group

Kelly W. Maloney, William L. Carroll, Andrew J. Carroll, Meenakshi Devidas, Michael J Borowitz, Paul L. Martin, Jeanette Pullen, James A. Whitlock, Cheryl L. Willman, Naomi J. Winick, Bruce M. Camitta, Stephen P. Hunger

Research output: Contribution to journalArticle

Abstract

Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and an inferior outcome. We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10. Eighty (3%) B-precursor ALL patients had DS. Age, sex, white blood cell count, and risk group were similar between DS-ALL and non-DS-ALL but significantly more patients with DS-ALL were white (91.2% vs 76.4%, P = .001). Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5% vs 24%, P <.001) and trisomies 4 and 10 (7.7% vs 24%, P <.001). Five-year event-free (EFS) and overall survival (OS) were inferior in children with DS-ALL: 69.9% ± 8.6% versus 78.1% ± 1.2% (P = .078), and 85.8% ± 6.5% versus 90.0% ± 0.9% (P = .033). However, when children with MLL translocations, BCR-ABL1, ETV6-RUNX1, and trisomies 4 and 10 were excluded, the EFS and OS were similar for children with and without DS (EFS 68.0 % ± 9.3% vs 70.5% ± 1.9%, P = .817; and OS 86.7% ± 6.7% vs 85.4% ± 1.5%; P = .852), both overall and adjusted for race. DS-ALL displays a unique spectrum of biologic subtypes with different frequencies of sentinel cytogenetic lesions having a large influence on outcome.

Original languageEnglish (US)
Pages (from-to)1045-1050
Number of pages6
JournalBlood
Volume116
Issue number7
DOIs
StatePublished - Aug 19 2010

Fingerprint

Oncology
Down Syndrome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics
Chromosomes
Blood
Cells
Trisomy
Testing
Survival
cyhalothrin
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 4
Leukocyte Count

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome : A report from the Children's Oncology Group. / Maloney, Kelly W.; Carroll, William L.; Carroll, Andrew J.; Devidas, Meenakshi; Borowitz, Michael J; Martin, Paul L.; Pullen, Jeanette; Whitlock, James A.; Willman, Cheryl L.; Winick, Naomi J.; Camitta, Bruce M.; Hunger, Stephen P.

In: Blood, Vol. 116, No. 7, 19.08.2010, p. 1045-1050.

Research output: Contribution to journalArticle

Maloney, KW, Carroll, WL, Carroll, AJ, Devidas, M, Borowitz, MJ, Martin, PL, Pullen, J, Whitlock, JA, Willman, CL, Winick, NJ, Camitta, BM & Hunger, SP 2010, 'Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group', Blood, vol. 116, no. 7, pp. 1045-1050. https://doi.org/10.1182/blood-2009-07-235291
Maloney, Kelly W. ; Carroll, William L. ; Carroll, Andrew J. ; Devidas, Meenakshi ; Borowitz, Michael J ; Martin, Paul L. ; Pullen, Jeanette ; Whitlock, James A. ; Willman, Cheryl L. ; Winick, Naomi J. ; Camitta, Bruce M. ; Hunger, Stephen P. / Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome : A report from the Children's Oncology Group. In: Blood. 2010 ; Vol. 116, No. 7. pp. 1045-1050.
@article{5386319fe64a44119e2e952c1217c9d4,
title = "Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group",
abstract = "Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and an inferior outcome. We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10. Eighty (3{\%}) B-precursor ALL patients had DS. Age, sex, white blood cell count, and risk group were similar between DS-ALL and non-DS-ALL but significantly more patients with DS-ALL were white (91.2{\%} vs 76.4{\%}, P = .001). Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5{\%} vs 24{\%}, P <.001) and trisomies 4 and 10 (7.7{\%} vs 24{\%}, P <.001). Five-year event-free (EFS) and overall survival (OS) were inferior in children with DS-ALL: 69.9{\%} ± 8.6{\%} versus 78.1{\%} ± 1.2{\%} (P = .078), and 85.8{\%} ± 6.5{\%} versus 90.0{\%} ± 0.9{\%} (P = .033). However, when children with MLL translocations, BCR-ABL1, ETV6-RUNX1, and trisomies 4 and 10 were excluded, the EFS and OS were similar for children with and without DS (EFS 68.0 {\%} ± 9.3{\%} vs 70.5{\%} ± 1.9{\%}, P = .817; and OS 86.7{\%} ± 6.7{\%} vs 85.4{\%} ± 1.5{\%}; P = .852), both overall and adjusted for race. DS-ALL displays a unique spectrum of biologic subtypes with different frequencies of sentinel cytogenetic lesions having a large influence on outcome.",
author = "Maloney, {Kelly W.} and Carroll, {William L.} and Carroll, {Andrew J.} and Meenakshi Devidas and Borowitz, {Michael J} and Martin, {Paul L.} and Jeanette Pullen and Whitlock, {James A.} and Willman, {Cheryl L.} and Winick, {Naomi J.} and Camitta, {Bruce M.} and Hunger, {Stephen P.}",
year = "2010",
month = "8",
day = "19",
doi = "10.1182/blood-2009-07-235291",
language = "English (US)",
volume = "116",
pages = "1045--1050",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome

T2 - A report from the Children's Oncology Group

AU - Maloney, Kelly W.

AU - Carroll, William L.

AU - Carroll, Andrew J.

AU - Devidas, Meenakshi

AU - Borowitz, Michael J

AU - Martin, Paul L.

AU - Pullen, Jeanette

AU - Whitlock, James A.

AU - Willman, Cheryl L.

AU - Winick, Naomi J.

AU - Camitta, Bruce M.

AU - Hunger, Stephen P.

PY - 2010/8/19

Y1 - 2010/8/19

N2 - Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and an inferior outcome. We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10. Eighty (3%) B-precursor ALL patients had DS. Age, sex, white blood cell count, and risk group were similar between DS-ALL and non-DS-ALL but significantly more patients with DS-ALL were white (91.2% vs 76.4%, P = .001). Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5% vs 24%, P <.001) and trisomies 4 and 10 (7.7% vs 24%, P <.001). Five-year event-free (EFS) and overall survival (OS) were inferior in children with DS-ALL: 69.9% ± 8.6% versus 78.1% ± 1.2% (P = .078), and 85.8% ± 6.5% versus 90.0% ± 0.9% (P = .033). However, when children with MLL translocations, BCR-ABL1, ETV6-RUNX1, and trisomies 4 and 10 were excluded, the EFS and OS were similar for children with and without DS (EFS 68.0 % ± 9.3% vs 70.5% ± 1.9%, P = .817; and OS 86.7% ± 6.7% vs 85.4% ± 1.5%; P = .852), both overall and adjusted for race. DS-ALL displays a unique spectrum of biologic subtypes with different frequencies of sentinel cytogenetic lesions having a large influence on outcome.

AB - Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and an inferior outcome. We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10. Eighty (3%) B-precursor ALL patients had DS. Age, sex, white blood cell count, and risk group were similar between DS-ALL and non-DS-ALL but significantly more patients with DS-ALL were white (91.2% vs 76.4%, P = .001). Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5% vs 24%, P <.001) and trisomies 4 and 10 (7.7% vs 24%, P <.001). Five-year event-free (EFS) and overall survival (OS) were inferior in children with DS-ALL: 69.9% ± 8.6% versus 78.1% ± 1.2% (P = .078), and 85.8% ± 6.5% versus 90.0% ± 0.9% (P = .033). However, when children with MLL translocations, BCR-ABL1, ETV6-RUNX1, and trisomies 4 and 10 were excluded, the EFS and OS were similar for children with and without DS (EFS 68.0 % ± 9.3% vs 70.5% ± 1.9%, P = .817; and OS 86.7% ± 6.7% vs 85.4% ± 1.5%; P = .852), both overall and adjusted for race. DS-ALL displays a unique spectrum of biologic subtypes with different frequencies of sentinel cytogenetic lesions having a large influence on outcome.

UR - http://www.scopus.com/inward/record.url?scp=77954491626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954491626&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-235291

DO - 10.1182/blood-2009-07-235291

M3 - Article

VL - 116

SP - 1045

EP - 1050

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -